Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD3 | Q15059 | 5/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | CASP6 | P55212 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.47 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | CDC42 | P60953 | 1/20 | 0.45 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.42 |
| ▸ | DHODH | Q02127 | 1/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.39 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.39 |
| ▸ | FPR3 | P25089 | 1/20 | 0.39 |
| ▸ | FPR2 | P25090 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22529416 | 1.00 | BRD3 (0.49) | BRD3GAACASP6CYP2D6PRMT5 | |
| SCHEMBL20615752 | 0.97 | BRD3 (0.52) | BRD3GAACASP6CYP2D6PRMT5 | |
| SCHEMBL30787999 | 0.95 | BRD3 (0.47) | BRD3GAACASP6CYP2D6PRMT5 | |
| SCHEMBL30787997 | 0.95 | BRD3 (0.47) | BRD3GAACASP6CYP2D6PRMT5 | |
| SCHEMBL20615443 | 0.93 | BRD3 (0.55) | BRD3GAACASP6CYP2D6PRMT5 | |
| SCHEMBL28488714 | 0.91 | BRD3 (0.49) | BRD3GAACASP6CYP2D6PRMT5 | |
| SCHEMBL28488268 | 0.88 | CYP2D6 (0.47) | BRD3GAACASP6CYP2D6PRMT5 | |
| SCHEMBL22529443 | 0.86 | CYP2D6 (0.55) | BRD3GAACASP6CYP2D6PRMT5 | |
| SCHEMBL28494320 | 0.85 | CYP2D6 (0.46) | BRD3GAACASP6CYP2D6PRMT5 | |
| SCHEMBL28494318 | 0.85 | CYP2D6 (0.46) | BRD3GAACASP6CYP2D6PRMT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11845742-B2 | Therapeutic compounds and methods to treat infection | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2023-12-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11845742-B2 | Therapeutic compounds and methods to treat infection | ABCB11, SLC47A1, SLC47A2 | BRD3 3949/4885GAA 143/4885CASP6 1190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.